Our vacancies

Máxima Butterfly MSCA program: looking for 28 PhD students in pediatric oncology

FAQ

For frequently asked questions, please follow the “read more” button on the right.

How to apply

The application must be submitted via www.maximabutterfly.com before January 31^st 2023 by 23:59 hours CET by using the electronic application form. Please follow the guidelines in the PDF documents below.

Download PDF

Guide for Applicants

CV template (mandatory)

Redress form

Timeline

Application open

1^st December 2022 – 31st January 2023 23:59 CET

Eligibility Check

Feb 1^st – Feb 15^th 2023

Assessment process 1

Feb 16^th – March 2^nd 2023

One-way video interviews

March 10^th – March 24^th

Assessment process 2

March 27^th – April 10^th

Interviews

April 17^th – May 1^st

Final assessment and results

May 1^st – May 15^th

Start of PhD projects

June 2023 – October 2023

current vacancies

Máxima Butterfly MSCA program: looking for 28 PhD students in pediatric oncology (Netherlands)

Máxima Butterfly MSCA program:

17. Artificial intelligence to enhance radiotherapy treatment planning for children with renal tumors.

Marry van den Heuvel-Eibrink/Geert Janssens

16. Genetic susceptibility and prevention of cisplatin-induced hearing loss in childhood cancer patients

Marry van den Heuvel-Eibrink

12. A game of hide and seek: targeting neuroblastoma’s escape from immunotherapy

Jan Molenaar / Judith Wienke

4A. Improving imaging techniques for childhood craniopharyngioma to better predict hypothalamic outcome.

Wim Tissing

4B. Biomarkers for early detection of bacterial infection in children with cancer

Wim Tissing

5A. Crossing the blood-brain barrier for local immune modulation of the tumour micro-environment by innovative drug delivery methods

Dannis van Vuurden

5B. Crossing barriers with multi-drug therapy in high-grade brain tumours

Dannis van Vuurden

6A. ALL, leukemic niche and oncogenomics

Monique den Boer

6B. Oncogenetic lesions affecting susceptibility to (immuno)therapy in ALL

Monique den Boer

7A. The osteochondral niche: how acute lymphoblastic leukaemia cells reshape skeletal stem cell differentiation to create a supportive and protective niche?

Olaf Heidenreich/Josef Vormoor/Mauricio Ferrao Blanco

7B. RAS signalling in the leukemic niche

Olaf Heidenreich/Josef Vormoor/Mauricio Ferrao Blanco

28A. Advancing cellular immunotherapies for Diffuse Midline Glioma using BEHAV3D, a multi-omics 3D image-based platform

Anne Rios

28B. Advancing DMG-midbrain organoids to model crosstalk between DMG and the human brain microenvironment

Anne Rios

9A. Amino acid depletion therapies for T cell Acute Lymphoblastic Leukemia

Frank van Leeuwen

9B. Identifying synthetic lethal combination therapies for TP53 deleted ALL using isogenic cell line models

Frank van Leeuwen

10A. Characterization of the immune microenvironment of rhabdomyosarcoma for the development of immunotherapy

Jarno Drost

10B. Immunomodulation of SWI/SNF-mutated pediatric malignancie

Jarno Drost

11A. Normal and aberrant germ cell development

Leendert Looijenga

11B. Germ cell tumors: optimal diagnosis and follow up based on understanding epidemiology and pathogenesis.

Leendert Looijenga

13. Targeting aberrant ATRX to identify new treatment options for Neuroblastoma

Jan Molenaar / Marlinde van den Boogaard

19A. The use of organotypic tissue slices for assessing prevention against treatment-induced side-effects via nutritional preconditioning interventions

Jan Hoeijmakers

19B. Aging-related transcription stress in chemotherapy-induced Dementia’s

Jan Hoeijmakers

20A. Psychosocial risk screening across the trajectory of childhood cancer treatment

Martha Grootenhuis

20B. Implementation of psychosocial risk screening for children with cancer and their parents during and after treatment

Martha Grootenhuis

21A. DIS3L2-mediated Wilms tumor predisposition and the role of non-coding RNAs

Roland Kuiper

21B. Tumor-based molecular signatures of childhood cancer predisposition

Roland Kuiper

26A. Tracking the origin of childhood cancer

Ruben van Boxtel

26B. The mutational consequences of cancer treatment and the evolution towards therapy-related leukaemia

Ruben van Boxtel

22A. Risk and protective factors of neurocognitive development in young children with cancer

Marita Partanen

22B. Machine learning approaches to improve prediction of neuropsychological outcome in pediatric cancer groups

Marita Partanen

23A. A life without blood: Single-cell analysis of childhood myelodysplastic syndrome to uncover therapeutic targets

Mirjam Belderbos/ Olaf Heidenreich

23B. Clonal evolution and therapeutic vulnerability of UBTF-mutated MDS/AML

Mirjam Belderbos/ Olaf Heidenreich

24A. Immunomodulation of Ewing sarcoma

Hans Clevers/Karin Sanders

24B. The transforming mechanism of Small Round Cell sarcomas